A detailed history of Becker Capital Management Inc transactions in Amgen Inc stock. As of the latest transaction made, Becker Capital Management Inc holds 90,731 shares of AMGN stock, worth $25.4 Million. This represents 0.96% of its overall portfolio holdings.

Number of Shares
90,731
Previous 92,797 2.23%
Holding current value
$25.4 Million
Previous $29 Million 0.83%
% of portfolio
0.96%
Previous 1.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$309.38 - $337.38 $639,179 - $697,027
-2,066 Reduced 2.23%
90,731 $29.2 Million
Q2 2024

Aug 13, 2024

SELL
$262.75 - $319.31 $793,767 - $964,635
-3,021 Reduced 3.15%
92,797 $29 Million
Q1 2024

May 15, 2024

SELL
$268.87 - $324.56 $815,213 - $984,065
-3,032 Reduced 3.07%
95,818 $27.2 Million
Q4 2023

Feb 14, 2024

SELL
$255.7 - $288.46 $1.35 Million - $1.53 Million
-5,289 Reduced 5.08%
98,850 $28.5 Million
Q3 2023

Nov 14, 2023

SELL
$218.65 - $271.46 $486,277 - $603,727
-2,224 Reduced 2.09%
104,139 $28 Million
Q2 2023

Aug 11, 2023

SELL
$214.27 - $253.37 $1.47 Million - $1.74 Million
-6,862 Reduced 6.06%
106,363 $23.6 Million
Q1 2023

May 15, 2023

SELL
$225.79 - $275.2 $244,078 - $297,491
-1,081 Reduced 0.95%
113,225 $27.4 Million
Q4 2022

Feb 13, 2023

SELL
$229.03 - $291.01 $1.39 Million - $1.77 Million
-6,076 Reduced 5.05%
114,306 $30 Million
Q3 2022

Nov 14, 2022

BUY
$224.46 - $253.15 $457,225 - $515,666
2,037 Added 1.72%
120,382 $27.1 Million
Q2 2022

Aug 04, 2022

BUY
$230.71 - $256.74 $306,613 - $341,207
1,329 Added 1.14%
118,345 $28.8 Million
Q1 2022

May 12, 2022

BUY
$219.27 - $242.57 $761,086 - $841,960
3,471 Added 3.06%
117,016 $28.3 Million
Q4 2021

Feb 08, 2022

SELL
$198.88 - $227.6 $309,855 - $354,600
-1,558 Reduced 1.35%
113,545 $25.5 Million
Q3 2021

Oct 14, 2021

BUY
$212.27 - $248.7 $838,891 - $982,862
3,952 Added 3.56%
115,103 $24.5 Million
Q2 2021

Aug 12, 2021

BUY
$233.58 - $259.14 $645,147 - $715,744
2,762 Added 2.55%
111,151 $27.1 Million
Q1 2021

May 13, 2021

BUY
$221.91 - $258.6 $509,727 - $594,004
2,297 Added 2.17%
108,389 $27 Million
Q4 2020

Feb 10, 2021

BUY
$216.38 - $257.67 $104,078 - $123,939
481 Added 0.46%
106,092 $24.4 Million
Q3 2020

Nov 09, 2020

BUY
$234.65 - $260.95 $82,596 - $91,854
352 Added 0.33%
105,611 $26.8 Million
Q2 2020

Aug 11, 2020

SELL
$197.81 - $242.74 $87,234 - $107,048
-441 Reduced 0.42%
105,259 $24.8 Million
Q1 2020

May 07, 2020

BUY
$182.24 - $241.7 $1.03 Million - $1.36 Million
5,645 Added 5.64%
105,700 $21.4 Million
Q4 2019

Feb 11, 2020

SELL
$189.21 - $243.2 $251,460 - $323,212
-1,329 Reduced 1.31%
100,055 $24.1 Million
Q3 2019

Nov 14, 2019

SELL
$174.11 - $208.62 $507,878 - $608,544
-2,917 Reduced 2.8%
101,384 $19.6 Million
Q2 2019

Aug 08, 2019

SELL
$166.7 - $195.41 $2,167 - $2,540
-13 Reduced 0.01%
104,301 $19.2 Million
Q1 2019

May 08, 2019

SELL
$180.87 - $203.88 $387,604 - $436,914
-2,143 Reduced 2.01%
104,314 $19.8 Million
Q4 2018

Feb 04, 2019

SELL
$178.4 - $208.25 $781,927 - $912,759
-4,383 Reduced 3.95%
106,457 $20.7 Million
Q3 2018

Nov 05, 2018

SELL
$185.29 - $208.89 $199,001 - $224,347
-1,074 Reduced 0.96%
110,840 $23 Million
Q2 2018

Aug 03, 2018

SELL
$166.05 - $186.51 $1.01 Million - $1.13 Million
-6,057 Reduced 5.13%
111,914 $20.7 Million
Q1 2018

May 07, 2018

BUY
$169.43 - $198.0 $5,252 - $6,138
31 Added 0.03%
117,971 $20.1 Million
Q4 2017

Feb 13, 2018

SELL
$168.79 - $188.59 $475,987 - $531,823
-2,820 Reduced 2.34%
117,940 $20.5 Million
Q3 2017

Nov 02, 2017

SELL
$167.29 - $191.0 $329,226 - $375,888
-1,968 Reduced 1.6%
120,760 $22.5 Million
Q2 2017

Aug 11, 2017

BUY
N/A
122,728
122,728 $21.1 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $150B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Becker Capital Management Inc Portfolio

Follow Becker Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Becker Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Becker Capital Management Inc with notifications on news.